

Press Release

Medigene AG to be included in TecDAX Index

Martinsried/München, 6 December 2016. [Medigene AG](#) (Frankfurt, Prime Standard, MDG1) has been selected for inclusion on the TecDAX, an index of the Deutsche Börse (German Stock Exchange) that includes Germany's most important mid-cap technology companies. The TecDAX follows the Blue Chip DAX index and comprises 30 companies admitted to the stock market "Prime Standard" segment. In addition to compliance with comprehensive international transparency requirements, the admission criteria include an above-average market capitalization (share price multiplied by the number of company shares), and a high trading volume (number of shares traded daily). According to the decision made by Deutsche Börse on 5 December 2016, Medigene has fulfilled the admission criteria for the TecDAX and will be included there as of 19 December 2016.

Prof Dolores Schendel, CEO of Medigene AG, comments: „TecDAX membership signifies Medigene's position among the leading German technology securities. This admission reflects the dynamic development Medigene has made following its strategic refocussing on the development of highly innovative cancer immunotherapies. The TecDAX listing increases Medigene's visibility in the capital markets and facilitates our collaboration with domestic and international investors.”

Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. The Company develops highly innovative, complementary treatment platforms to target various forms and stages of cancer with drug candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalized T-cell-based immunotherapies.

More information is available at www.medigene.de

This press release contains certain statements relating to the future. They represent the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be held or licensed for specific countries.

Contact Medigene

Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com

Should you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.